Each year in the United States, over 1.5 million people sustain a traumatic brain injury.  These devastating injuries can result in long-term clinical problems including a loss of motor function as well as severe cognitive abnormalities.  TBI’s can be varied in intensity including mild, moderate and severe.  Over the last decade, scientists have demonstrated the abnormal inflammatory cascades may participate in secondary injury mechanisms after TBI.  Thus, many investigators are evaluating novel therapeutic interventions that can target these deleterious inflammatory events that could then improve outcome.

Neurotrauma

In the area of spinal cord injury, over 11,000 new patients sustained a severe SCI each year in the United States.  Because young men are most frequently injured by spinal cord injury, they are left with severe disabilities for many years that limit their ability to contribute to society.  As with traumatic brain injury, spinal cord injury also produces a variety of inflammatory events that lead to secondary injury mechanisms.  The vision of InflamaCORE is to develop therapeutic interventions that can target the very early cellular events associated with inflammasome activation leading to downstream deleterious secondary events.  Because currently, there are no FDA approved therapies to target TBI or spinal cord injury, this research area appears to be especially important for new drug discovery.